Seegene Inc, a leading South Korean company providing a total solution for molecular diagnostics through PCR, announced that Professor Dame Jenny Harries, CEO of the UK Health Security Agency (UKHSA), visited their headquarters in Seoul, Korea on March 27.
During the visit, Professor Harries and her delegation met with Dr. Jong-Yoon Chun, founder and CEO of Seegene, and the management team. They expressed their strong determination to collectively work towards realizing Seegene’s vision of “a world free from all diseases.”
Professor Harries expressed keen interest in Seegene’s SG OneSystemTM activity, the company’s technology-sharing initiative, as well as its advancements in AI-based automated diagnostic reagent development system and innovative digital solutions that integrate biotechnology and information technology.
Highlighting Seegene’s rapid response to the COVID-19 pandemic, Professor Harries praised the company’s agility in developing diagnostic reagents in just three weeks and distributing them globally. Seegene facilitated the rapid and effective isolation of COVID-19 infected individuals by delivering approximately 350 million diagnostic tests to over 100 countries.
“We greatly appreciate the visit of UKHSA, a leading health security agency, to Seegene headquarters,” said Dr. Chun. “We will continue to explore ways to contribute to cooperation between Korea and the UK, including through our SG OneSystemTM activity.”
Seegene’s SG OneSystemTM activity is a global strategy aimed at eradicating diseases by sharing quantitative syndromic PCR technology and Seegene’s digital development system (SGDDS) with leading companies worldwide. This initiative allows scientists from around the world to directly contribute to the development of locally tailored diagnostic reagents for various diseases affecting humans, animals, and plants.
To effectively advance this initiative, Seegene has established strategic collaborations with industry and academic leaders, including Microsoft and Springer Nature, showcasing its commitment to advancing global health solutions through the improvement of its technology-sharing initiative.
Source: PRNewswire
Seegene Inc, a South Korean company that specializes in molecular diagnostics through PCR, recently had a visit from Professor Dame Jenny Harries, CEO of the UK Health Security Agency (UKHSA). This visit signifies the mutual interest in working towards Seegene’s vision of a disease-free world.
During the visit, Professor Harries and her delegation met with Dr. Jong-Yoon Chun, founder and CEO of Seegene, to discuss various aspects of the company’s work. They were particularly interested in Seegene’s SG OneSystemTM activity, which is a technology-sharing initiative. Additionally, they discussed the company’s advancements in AI-based automated diagnostic reagent development system and innovative digital solutions that integrate biotechnology and information technology.
One of the highlights of the meeting was Seegene’s rapid response to the COVID-19 pandemic. Professor Harries commended the company’s agility in developing diagnostic reagents in just three weeks and distributing them globally. Seegene played a crucial role in facilitating the isolation of COVID-19 infected individuals by delivering approximately 350 million diagnostic tests to over 100 countries.
Seegene’s SG OneSystemTM activity is a global strategy aimed at eradicating diseases by sharing syndromic PCR technology and the company’s digital development system with leading companies worldwide. This initiative allows scientists from different parts of the world to contribute to the development of tailored diagnostic reagents for various diseases that affect humans, animals, and plants.
To further enhance this initiative, Seegene has formed strategic collaborations with industry and academic leaders such as Microsoft and Springer Nature. These partnerships highlight Seegene’s commitment to advancing global health solutions through the improvement of its technology-sharing initiative.
This visit by Professor Harries and the discussions that took place reflect the importance of collaboration between countries and industries to combat diseases. It also underlines the significance of Seegene’s role in the global health security landscape.
For more information on Seegene and their work, please visit their website: Seegene.